Ono warns on profit after government halves price of cancer drug Opdivo

TOKYO (Reuters) - Ono Pharmaceutical Co cut its annual profit outlook by a quarter on Wednesday, hit by the Japanese government's decision to halve the price of cancer drug Opdivo that it co-developed with Bristol Myers Squibb Co.